Paper: Protecting investment in biologic medicines – biological medicines, biosimilars and the challenges they pose
15 September 2016
In Brief: This series of articles is directed towards the part of biotech that is ‘pharmaceutical’, rather than diagnostic or bioengineering technologies, and, in particular, towards biologic medicines.
These are medicines that have been made or modified using biological systems, ie living organisms or their derivatives.
- Ric MorganSpecial Counsel,
Ph: +61 3 9613 8425